News | August 06, 2025
Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Cenexi reports an EBITDA breakeven for the quarter
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Subscribe To Our Newsletter & Stay Updated
